Karnataka govt to hold first of it's kind virtual job fair on July 10

Mangaluru, Jun 29: An elderly woman who was tested positive for coronavirus, breathed her last at the designated covid hospital in the city today.

The deceased was a 60-year-old resident of Ullal.

According to sources, the woman, was getting treated for ailments related to liver and heart.

More details awaited:

Bengaluru, Jan 11: The Chief Justice of India Justice Sharad Arvind Bobde on Saturday inaugurated the phase-1 of the new building of the Karnataka Judicial Academy on Crescent Road in Bengaluru.

The new building has three floors, besides, the ground floor and two basement floors.

While Chief Minister B S Yediyurappa inaugurated the 319-seater multi-purpose auditorium, at which Chief Justice of the High Court of Karnataka Justice Abhay Shreeniwas Oka felicitated Justice Bobde.

Justice Ravi Malimath, President of the Karnataka Judicial Academy and Judge of the High Court of Karnataka, in his welcome address said that the academy has so far trained as many as 4000 judicial officers and striving for excellence in the field of judiciary.

The building, built in the first phase, has parking in the lower and the upper basement, which can accommodate 44 cars and 124 two-wheelers, the ground floor consists of a 319-seater multi-purpose air-conditioned auditorium, a lecture hall with 84 seats, two lecture halls with 40 seats each and a VIP lounge. The First Floor has a lecture hall with 84 seats, two lecture halls with 40 seats each, a VIP lounge, two discussion rooms and an administrative office for the staff of the academy.

The second phase, to be built has a parking facility for 36 four-wheelers and 22 two-wheelers in the lower basement and 32 four-wheelers and 30 two-wheelers in the upper basement.

The total cost of the project, including Phase-1 and Phase-2, to be executed by the Public Works Department in the sprawling 2.2 acres plot of the Karnataka Judicial Academy is around Rs 96.02 Crore.

The United States of America has bought almost the entire world's supply of remdesivir, one of just two drugs proven to treat COVID-19. 

“President Trump has struck an amazing deal to ensure Americans have access to the first authorised therapeutic for Covid-19,” said the US health and human services secretary, Alex Azar. 

“To the extent possible, we want to ensure that any American patient who needs remdesivir can get it. The Trump administration is doing everything in our power to learn more about life-saving therapeutics for Covid-19 and secure access to these options for the American people.”

The announcement implies that no other country in the world will be able to buy remdesivir for next three months at least.

The anti-viral drug patented by the US-based Gilead biotech firm is the only one approved by the European Medicines Agency (EMA) to treat patients with the novel coronavirus.

The Trump administration has already shown that it is prepared to outbid and outmanoeuvre all other countries to secure the medical supplies it needs for the US.

“They’ve got access to most of the drug supply [of remdesivir], so there’s nothing for Europe,” said Dr Andrew Hill, senior visiting research fellow at Liverpool University.

Remdesivir, the first drug approved by licensing authorities in the US to treat Covid-19, is made by Gilead and has been shown to help people recover faster from the disease. 

The first 140,000 doses, supplied to drug trials around the world, have been used up. The Trump administration has now bought more than 500,000 doses, which is all of Gilead’s production for July and 90% of August and September.